Breakfast Symposium 1
Breakfast Symposium 2
Breakfast Symposium 3
Breakfast Symposium 4
Symposium 11
AAS-KSoLA Joint Symposium
Symposium 12
Symposium 13
Plenary Lecture 1
Special Lecture 1
Luncheon Symposium 1
Luncheon Symposium 2
Luncheon Symposium 3
Luncheon Symposium 4
Oral Presentation 2
Symposium 14
Symposium 15
Symposium 16
Keynote Lecture 1
Symposium 17
VAS-KSoLA Joint Symposium
Symposium 18
Symposium 19
09. 12(Fri)
09. 12(Fri) 07:30~08:30 Room 1
09. 12(Fri) 07:30~08:30 Room 2
09. 12(Fri) 07:30~08:30 Room 3
09. 12(Fri) 08:30~10:00 Room 1
Genetic Insights into Dyslipidemia: Pathways, Predictions, and Interventions
- Exloring the genetic landscape of CVD and dyslipidemia: finding and future implication 08:30~08:50
- Prioritization of therapeutic targets for dyslipidemia using integrative multi-omics and multi-trait analysis 08:50~09:10
- Recent progress in gene therapy for familial hypercholesterolemia treatment 09:10~09:30
- Panel Discussion 09:30~10:00
09. 12(Fri) 08:30~10:00 Room 2
Comprehensive Strategies for the Prevention of Atherosclerosis: Current Insights and Future Directions
- Inflammation and atherosclerosis: emerging biomarkers and anti-inflammatory therapies 08:30~08:50
- The role of digital health technology in managing atherosclerosis: a new frontier 08:50~09:10
- Impact of lipid-lowering therapy on aortic aneurysm progression and cardiovascular outcomes 09:10~09:30
- Panel Discussion 09:30~10:00
09. 12(Fri) 08:30~10:00 Room 3
TBD
09. 12(Fri) 08:30~10:00 Room 4
TBD
09. 12(Fri) 10:20~11:00 Room 1,2,3
09. 12(Fri) 11:05~11:45 Room 1,2,3
09. 12(Fri) 12:00~13:00 Room 3
09. 12(Fri) 13:00~14:30 Room 1
09. 12(Fri) 13:00~14:30 Room 2
What is Important beyond Stenosis in Intracranial Atherosclerosis
09. 12(Fri) 13:00~14:30 Room 3
Nontraditional Risk Factors for ASCVD
- Environmental pollution as a nontraditional risk factor for atherosclerotic cardiovascular disease: mechanisms and impacts 13:00~13:20
- Health inequity and its role as a nontraditional risk factor in the prevalence and severity of ASCVD 13:20~13:40
- Sleep disorders: an overlooked nontraditional risk factor in atherosclerotic cardiovascular disease development 13:40~14:00
- Panel Discussion 14:00~14:30
09. 12(Fri) 13:00~14:30 Room 4
Defining the Optimal LDL-C Target for Prevention of Atherosclerotic Cardiovascular and Cerebrovascular Disease
- Optimal LDL-C goals for secondary prevention in high-risk patients - a cardiologist’s perspective 13:00~13:20
- Optimal LDL-C level for stroke prevention - insights from a neurologist’s perspective 13:20~13:40
- Different LDL-C targets by duration of diabetes: what is the evidence? - an endocrinologist’s perspective 13:40~14:00
- Panel Discussion 14:00~14:30
09. 12(Fri) 15:50~16:30 Room 1,2,3
09. 12(Fri) 16:45~18:15 Room 1
Emerging Drugs for Dyslipidemia Management
09. 12(Fri) 16:45~18:15 Room 2
Lipid-Lowering Strategies: Targets and Therapies in Clinical Practice
- Triglyceride and HDL-C focus in Asian populations: rethinking priorities? 16:45~17:05
- Combination lipid-lowering therapy: when statins alone are not enough 17:05~17:25
- Ethnic differences in managing dyslipidemia: tailoring treatment strategies for Asian and Western populations 17:25~17:45
- Panel Discussion 17:45~18:15
09. 12(Fri) 16:45~18:15 Room 3
Sex and Gender Differences in Cardiometabolic Health: From Biology to Treatment
09. 12(Fri) 16:45~18:15 Room 4
Emerging Complexities in Adipose Tissue Metabolism and Physiology
